Our results provide evidence from the Chinese population that blood biomarkers measured with ultrasensitive assays have potential value in Alzheimer’s disease diagnosis and differentiation, particularly P-tau181 for discriminating from SIVD and GFAP for discriminating from FTLD. This evidence concerns the gene GFAP and Alzheimer disease.